Introduction
Clostridium difficile infection (CDI) is an emerging disease in the Western world and affects .25000 people annually in England and .250 000 hospitalized patients per year in the USA.
1,2 Symptoms vary from mild diarrhoea to a severe pseudomembranous colitis. Reported mortality due to CDI varies from 6% of the patients in endemic situations to 17% in outbreak settings in which the hypervirulent PCR ribotype 027 (NAP-1) is involved. 3, 4 Known risk factors for CDI are previous hospitalization, advanced age (.65 years) and, most importantly, the use of antibiotics. Several antibiotic classes have been associated with the development of CDI, including clindamycin, cephalosporins and fluoroquinolones. 5, 6 Furthermore, the number of administered antibiotics, their dosage and the duration of therapy were previously identified as factors determining the risk for CDI. 7 -9 An important question that remains unanswered concerns the time interval of increased risk for CDI after exposure to antibiotics.
In recent studies, patients were defined as 'antibiotic users' when they used an antibiotic 'several days' up to '3 months' before CDI was diagnosed. 10 -13 A study among a selected population of elderly patients who were admitted due to severe community-acquired CDI, however, suggested that the period of increased risk for CDI was ≥30 days.
14 Detailed knowledge about the risk of CDI after antibiotic exposure can aid clinicians to select high-risk patients, improve antimicrobial stewardship and, consequently, decrease the incidence of CDI. 15 Furthermore, this knowledge can help future research to operate with a more appropriate definition of antibiotic use. Therefore, we evaluated risk factors for CDI in a multicentre case-control study with special interest for the precise time interval of increased risk for CDI after exposure to antibiotics.
Methods
Patients and data collection and University Medical Center Utrecht (Utrecht). During a minimum of six consecutive months (within the study period of .3 years), a participating hospital included all hospitalized CDI patients in the study. According to the proposed definitions, case patients were defined as patients with diarrhoea and a positive test for C. difficile toxin. 16 Diarrhoea was defined as three or more unformed stools (taking the shape of the container) per day. For each CDI patient, two control patients were selected: one patient with diarrhoea and a negative test for C. difficile (non-CDI diarrhoea) and one patient without diarrhoea (non-diarrhoeal). CDI and control patients were matched for hospital, ward and time of diagnosis, which implied selection of control patients that were hospitalized within 14 days of the day on which CDI was diagnosed in the case patient. When several potential control patients were eligible, the first patient on the alphabetical ward list was chosen. A non-CDI diarrhoeal patient was not always available at the time of selection. Patients could participate in the study only once.
The Medical Review Ethics Committee of each participating hospital approved the study. No informed consent was required, because only data were used that were available as part of regular patient care. We extracted information on patients' age, sex, comorbidity and ward of acquisition, previous use of antibiotics (name of drug, dosage, duration of therapy and dispensing dates), co-medication (gastric acid suppressors, non-steroidal anti-inflammatory drugs, immunosuppressive therapy and chemotherapy), admissions and invasive procedures. We used a time period of 3 months for previous use of medications, admissions and procedures. For CDI patients and for non-CDI diarrhoeal patients, this period was defined as the 3 months prior to the start of diarrhoea. For non-diarrhoeal patients, we used a 3 month period prior to a reference date, which was determined by adding the hospitalized period of the matched CDI patient (time between admission and start of diarrhoea) to the admission date of the non-diarrhoeal patient. Using a standardized questionnaire, the data were collected by consulting the physician in charge, using the electronic medical information system and individual patient records. Patients whose records regarding antibiotic use were missing (n¼9) were excluded from the study.
Antibiotics were classified into 11 categories (depicted in Table 2 ). The category 'others' comprised tetracyclines, rifamycins, polymyxins and lipopeptides. We combined the duration and dosage of each prescribed antibiotic by calculation of the defined daily dose (DDD), using a computer tool to calculate antibiotic consumption (ABC Calc 3.1b, available at www.escmid.org/esgap). Comorbidity was assessed by both the Charlson comorbidity index and the ICD-10 diagnosis, using the 10th revision of the International Classification of Diseases; mentioned in Table 1 . 17 
Microbiological analysis
Tests for CDI were performed upon the request of the physician and on all unformed faecal samples from patients who had been admitted for ≥2 days, regardless of the physician request. According to the standard of the local hospital, one of the following C. difficile tests was used: VIDAS C. difficile toxin A (bioMérieux), VIDAS C. difficile toxin A&B (bioMér-ieux), Premier C. difficile toxins A&B (Meridian), ImmunoCard C. difficile (Meridian) or cytotoxicity assay. Toxin-positive faecal samples were cultured for the presence of C. difficile using a standardized protocol supplied by LUMC. Confirmation of C. difficile was performed at LUMC by detection of the gluD gene. 18 C. difficile isolates were further characterized by PCR ribotyping, as previously described. 19 
Statistical analysis
We compared cases with controls without diarrhoea. To determine the period of increased risk for diarrhoea after antibiotic therapy, we also compared cases with non-CDI diarrhoeal patients. We present both comparisons, since the results of the first comparison slightly overestimate the effect of antibiotic therapy on the development of CDI and the comparison of cases with non-CDI controls will underestimate this effect, because diarrhoea is a frequent side effect of antibiotic therapy.
Binominal characteristics were compared using the x 2 test. In all other analyses the individual matching was taken into account. The association between CDI and antibiotic use was analysed using conditional logistic regression, adjusting for age (in three categories), sex and Charlson comorbidity index (in four categories). In the evaluation of a single antibiotic class this method is referred to as Method 1. Additional adjustments for the use of concomitant antibiotics of different classes were made in the evaluation of a single antibiotic class as a risk factor for CDI by entering all other antibiotic classes into one multivariable model (Method 2). Results are presented as ORs with the accompanying 95% CI. Because we performed concurrent sampling for the selection of controls, the OR is identical to the rate ratio. 20 Statistical significance was reached with a two-sided P value ,0.05. We analysed additive interaction between second-and third-generation cephalosporins and other antimicrobial classes by calculating the synergy index. 21 We used PASW Statistics version 17.0 (SPSS Inc., Chicago, IL, USA) and STATA software package 10.1 (StataCorp, College Station, TX, USA) for our analyses.
Results

Patient characteristics
A total of 337 CDI patients were included and matched to 337 non-diarrhoeal controls and 227 non-CDI diarrhoeal controls. Clinical and demographic data were complete for the majority of patients (2.7% missing data). The baseline characteristics of the included patients are shown in Table 1 .
The CDI patients had a mean age of 61.8 years, compared with 59.5 and 58.1 years in non-diarrhoeal patients and non-CDI controls, respectively. The CDI patients more frequently had a previous admission to a healthcare facility and more frequently used antibiotics, immunosuppressants and cytostatic agents than non-diarrhoeal controls. All underlying diseases were more prevalent among CDI patients. The prevalence of diseases of the digestive and genitourinary systems differed the most, and these were present among 27.2% and 35.4% of the CDI patients and among 17.2% and 22.6% of the non-diarrhoeal patients, respectively (both P,0.01). Non-CDI diarrhoeal patients more frequently had diseases of the digestive system compared with patients with CDI (29.1% versus 27.2%; P ¼ 0.62).
Risk for CDI after antibiotic use 743 JAC Table 2 . Characteristics of antibiotic use in patients with CDI, control patients without diarrhoea and patients with non-CDI diarrhoea Use of antibacterial classes in the 3 months prior to CDI CDI patients (N¼337) Non-diarrhoeal patients (N¼337) Non-CDI patients (N ¼227) Time between the use of the last antibiotic and the start of diarrhoea/reference date; unknown for an additional 35 patients. Antibiotic use was defined as the use of any antibiotic during the 3 month period prior to the start of diarrhoea or the reference date.
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Antibiotic agents and the risk for CDI
Type of antibiotic agent
Cephalosporins (mainly cefuroxime and ceftriaxone, both 19%) and penicillins (mainly co-amoxiclav, 48%) were the most frequently used antibiotics ( We therefore also evaluated the association between antibiotic classes and CDI after adjustment for concomitant use of antibiotics. After these adjustments, CIs overall widened, but second-and third-generation cephalosporins, penicillins, carbapenems and metronidazole remained significantly associated with CDI (Table 3 , third column). Furthermore, we performed an interaction analysis in which no synergistic effect of cephalosporins on any of the other antibiotic classes, or vice versa, was observed (data not shown).
Number of antimicrobials
CDI patients used more different antibiotic classes than nondiarrhoeal controls, with a mean of 2.7 versus 2.2 different classes, respectively (P,0.01). 
Duration and dosage
Period of increased risk
To determine the time interval of increased risk for CDI after exposure to antibiotics, we divided the 3 months prior to the reference date into six intervals (Figure 2 ). In the month prior to the reference date, 242 CDI patients used an antibiotic (76.8%), compared with 157 non-diarrhoeal patients (48.9%) (P,0.01). Of these, 110 CDI patients (35%) and 80 nondiarrhoeal patients (25%) used an antibiotic at the time of diagnosis (P ¼ 0.01). Multivariate analysis showed a .6-fold increased risk for CDI during antibiotic use and in the first month after cessation of the antibiotic therapy (OR 6.67 -10.37). This risk declined during the period between 1 and 3 months after the antibiotic was stopped (OR 2.72; 95% CI 1.20-6.15). Additionally, we have displayed the comparison of CDI patients versus non-CDI diarrhoeal patients in Figure 2 . This comparison also showed an increased risk for CDI in the first month after the cessation of antibiotic therapy (OR 5.24-9.35). When an antibiotic was used at the start of diarrhoea, the risk for CDI was lower (OR 2.41; 95% CI 1.30 -4.46), which can be explained by the occurrence of antibiotic-associated diarrhoea in non-CDI diarrhoeal patients. Risk for CDI after antibiotic use 745 
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Microbiological characteristics
Isolates from 211 (58%) CDI patients were available for further characterization. In 192 (91%) of these, we were able to perform PCR ribotyping. Type 014 was the most frequently found type (n¼ 34; 18%), followed by types 078 (n¼ 24; 13%), 001 (n¼ 17; 9%) and 027 (n¼ 16; 8%).
Discussion
In this multicentre case -control study, we analysed the period of increased risk for CDI after antibiotic therapy. We found a 7 -10-fold increased risk for CDI during antibiotic therapy and in the first month after cessation of antibiotics. Another important finding of our study was that antibiotic use 1 -3 months before the development of diarrhoea could still be associated with CDI. Second-and third-generation cephalosporins and carbapenems were the most potent risk factors. The risk for CDI increased when a larger amount of antibiotics and more antibiotic classes were used. Our findings regarding the time interval of increased risk are in accordance with the results of a previous study that investigated a specific patient population of elderly patients, who were admitted due to severe community-acquired CDI.
14 The generalizability of this Canadian study was limited, however, because it comprised only a small fraction of the patient population that was included in our study. The period of increased risk also coincided with changes in the gut microbiota that occur within days after the start of antibiotic therapy and can persist for weeks or even years after cessation of the antibiotic. 22, 23 Because the intact commensal bowel flora protects against intestinal colonization and infection by C. difficile, disruption of the flora during and after antibiotic therapy can result in outgrowth and toxin production by C. difficile.
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The duration of therapy and dosage of antibiotics, expressed as DDD, showed a positive correlation with the risk of CDI, which is in line with previous reports, as well as our finding that virtually all antibiotic classes were associated with CDI. 7, 8, 25 In the literature, fluoroquinolones have mainly been associated with CDI due to PCR ribotype 027. 25 Because we encountered this type in only 8% of our patients, this antibiotic class was not among the most potent risk factors in our study. First-generation cephalosporins, which are regularly used as a perioperative prophylaxis, were not associated with CDI in our analyses. This is in line with previous studies, where this antibiotic class was associated with a relatively small risk, or even a decreased risk, for the development of CDI. 8, 25, 26 The latter was suggested to be a result of not severely ill patients with short admissions who received small amounts of first-generation cephalosporins. Because cases and controls in our study were selected from the same department and patients receiving a Hensgens et al.
first-generation cephalosporin did not represent a specific population (same age and Charlson comorbidity index as patients not receiving this cephalosporin), we assume that first-generation cephalosporins affect the gut microbiota to a lesser extent and do not increase the risk for development of CDI. The administration of metronidazole or vancomycin has infrequently been associated with an increased risk for CDI. 8, 25 In the present study, most patients received intravenous metronidazole or vancomycin for systemic treatment of infections other than CDI, but 6.5% of the patients were treated orally. After excluding these patients, metronidazole and vancomycin remained associated with CDI, but the association became weaker (adjusted ORs 3.08 and 1.68 for metronidazole and vancomycin, respectively, according to Method 1).
One approach to analyse the risk for CDI associated with a certain antibiotic class is to restrict the analysis to cases and controls not using other antibiotics. Since only a minority of our CDI patients used antibiotic monotherapy (n¼ 36; 11%), this approach was not feasible. We therefore analysed the effect of a single class of antibiotics by including all cases and controls, and adjusting in a logistic model for the use of concomitant antibiotic classes. The advantage is an increased power of the analyses, because all cases and controls are included. The estimated ORs will be valid provided that confounding has been adequately adjusted for, a condition that cannot be proven empirically. 27 Confounding was, however, minimized by adjusting for all antibiotic classes.
The most important strength of this study is the robustness of the dataset that was generated by combining data from electronic medical systems, patient records and direct consultation of the physician. Furthermore, we reduced the ascertainment bias by testing all unformed stool samples, irrespective of the physician's request. Matching CDI patients and their controls on ward and time of admission ensured that these patients originated from a setting with a comparable CDI pressure, which has been described as an important risk factor for CDI. 28 Lastly, our results are applicable to non-outbreak situations, since the study was performed in a setting in which multiple PCR ribotypes caused CDI (39 different types).
A limitation of our study is the use of various enzyme immunoassays to diagnose CDI. The reported sensitivity of these tests varies between 60% and 85%. 29, 30 Therefore, patients in our study could have been missed as patients with CDI. Consequently, the time of increased risk of non-CDI diarrhoea after antibiotic use might have been overestimated. A second limitation of our study is the use of two control groups. About 10% of patients admitted to a (university) hospital experience diarrhoea during their admission. Therefore, a control group that would have been selected without considering the presence of diarrhoea would have been more representative. 31, 32 Analysis of our data after combining the control groups of patients with non-CDI diarrhoea and non-diarrhoeal patients, however, did not influence our conclusions (data not shown).
In conclusion, the interval of increased risk for CDI after antibiotic therapy comprises the time from the actual antibiotic use until 3 months thereafter. The highest risk for CDI is found during and in the first month after antibiotic use. Clinicians should be aware that antibiotic use can increase the risk for CDI 10-fold, even if the antibiotic use preceded the symptoms by 1 month. Additionally, the results of our study could help future researchers to more accurately define the period of increased risk for CDI after antibiotic exposure.
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